Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) Debt to Equity: 2018-2023

Historic Debt to Equity for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2023 value amounting to $0.00.

  • Autolus Therapeutics' Debt to Equity rose 150.81% to $0.00 in Q3 2023 from the same period last year, while for Sep 2023 it was $0.00, marking a year-over-year increase of 150.81%. This contributed to the annual value of $0.00 for FY2022, which is 4.93% down from last year.
  • Per Autolus Therapeutics' latest filing, its Debt to Equity stood at $0.00 for Q3 2023, which was up 207.19% from $0.00 recorded in Q2 2023.
  • In the past 5 years, Autolus Therapeutics' Debt to Equity registered a high of $0.00 during Q3 2023, and its lowest value of $0.00 during Q3 2019.
  • Moreover, its 3-year median value for Debt to Equity was $0.00 (2023), whereas its average is $0.00.
  • The largest annual percentage gain for Autolus Therapeutics' Debt to Equity in the last 5 years was 150.81% (2023), contrasted with its biggest fall of 6.61% (2023).
  • Autolus Therapeutics' Debt to Equity (Quarterly) stood at $0.00 in 2019, then reached $0.00 in 2021, then declined by 4.93% to $0.00 in 2022, then soared by 150.81% to $0.00 in 2023.
  • Its last three reported values are $0.00 in Q3 2023, $0.00 for Q2 2023, and $0.00 during Q1 2023.